{"id":"ceftazidime-avibactam","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime is a broad-spectrum cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and some carbapenemases, thereby restoring ceftazidime's activity against resistant gram-negative and gram-positive bacteria.","oneSentence":"Ceftazidime-avibactam is a combination of a third-generation cephalosporin antibiotic and a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:41.826Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria"},{"name":"Complicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"},{"name":"Aerobic gram-negative bacterial infections in patients with limited treatment options"}]},"trialDetails":[{"nctId":"NCT07494981","phase":"","title":"Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Ceftazidime-avibactam","enrollment":150},{"nctId":"NCT07478484","phase":"PHASE4","title":"Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB","status":"RECRUITING","sponsor":"Jing Zhou","startDate":"2026-03-31","conditions":"Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection","enrollment":144},{"nctId":"NCT07431307","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-07","conditions":"Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection","enrollment":120},{"nctId":"NCT07327619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-22","conditions":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia","enrollment":420},{"nctId":"NCT07369518","phase":"","title":"Effect of Ceftazidime-Avibactam on Carbapenemase-Producing Klebsiella Pneumoniae","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-01","conditions":"ISOLATION OF KLEB. by Culture on macConkey Agar, Antibiotic Sensitivity Testing of Different Antibiotics According to Clsi 25, Effect of Ceftazidime-Avibactam on Carbapenemase-Producing Klebsiella Pneumoniae","enrollment":100},{"nctId":"NCT06717594","phase":"","title":"PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-12-01","conditions":"Gram Negative Infections, Antimicrobial Resistance (AMR)","enrollment":60},{"nctId":"NCT06864585","phase":"","title":"A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-03-15","conditions":"Infectious Diseases","enrollment":59},{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT07160569","phase":"","title":"Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-09-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":100},{"nctId":"NCT05487586","phase":"","title":"Real-World Study of Ceftazidime Avibactam in China","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-10-20","conditions":"Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections","enrollment":220},{"nctId":"NCT05733104","phase":"","title":"A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-19","conditions":"Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia","enrollment":600},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05413343","phase":"","title":"Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-06-01","conditions":"Severe Sepsis","enrollment":30},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT06939829","phase":"PHASE4","title":"A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-05-01","conditions":"Patients With Critically Ill Infections","enrollment":1200},{"nctId":"NCT06811727","phase":"PHASE4","title":"CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients","status":"NOT_YET_RECRUITING","sponsor":"Ivan Šitum, MD","startDate":"2025-05-01","conditions":"Severe Infection","enrollment":140},{"nctId":"NCT06818565","phase":"NA","title":"Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-10","conditions":"Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":"Bacteremia","enrollment":265},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT06651047","phase":"","title":"PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","status":"RECRUITING","sponsor":"University of Bologna","startDate":"2024-07-09","conditions":"Gram Negative Infection, Antimicrobial Resistance (AMR)","enrollment":120},{"nctId":"NCT06633718","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Intra-abdominal Infections","enrollment":786},{"nctId":"NCT04774094","phase":"PHASE4","title":"Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-21","conditions":"Hospital-Acquired Pneumonia","enrollment":235},{"nctId":"NCT04785924","phase":"PHASE4","title":"Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2021-06-07","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections","enrollment":""},{"nctId":"NCT04628572","phase":"","title":"Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-29","conditions":"Gram Negative Infections","enrollment":189},{"nctId":"NCT06528028","phase":"PHASE4","title":"Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-07-01","conditions":"Anti-Infective Agent","enrollment":140},{"nctId":"NCT05566665","phase":"","title":"Nosocomial Infections in ECMO Patients","status":"RECRUITING","sponsor":"Policlinico Hospital","startDate":"2023-01-01","conditions":"Acute Respiratory Distress Syndrome, Nosocomial Infection, Extracorporeal Membrane Oxygenation Complication","enrollment":200},{"nctId":"NCT03923426","phase":"","title":"Real-World Observational Study Of Zavicefta to Characterize Use Patterns","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-27","conditions":"Infection","enrollment":572},{"nctId":"NCT05048693","phase":"","title":"Use of New Antibiotics in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-11-01","conditions":"Multi-antibiotic Resistance","enrollment":41},{"nctId":"NCT05258851","phase":"PHASE3","title":"Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2022-06-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":29},{"nctId":"NCT04126031","phase":"PHASE2","title":"Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-01-14","conditions":"Gram-negative Bacterial Infection","enrollment":48},{"nctId":"NCT04927312","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-01","conditions":"Complicated Intra-abdominal Infection","enrollment":60},{"nctId":"NCT05979545","phase":"PHASE4","title":"EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2023-12-12","conditions":"Blood Stream Infections, Ventilator Associated Pneumonia, Healthcare Associated Infection","enrollment":1900},{"nctId":"NCT06210542","phase":"","title":"Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2024-01","conditions":"ECMO, Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":50},{"nctId":"NCT05862402","phase":"PHASE4","title":"Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2023-05-07","conditions":"Carbapenem Resistant Klebsiella Pneumoniae","enrollment":76},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427},{"nctId":"NCT04040621","phase":"PHASE1","title":"Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-06-15","conditions":"Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia","enrollment":4},{"nctId":"NCT03978091","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-09","conditions":"Bacterial Infection","enrollment":48},{"nctId":"NCT03790176","phase":"PHASE1","title":"ZAVI APD ELF Protocol v2.2","status":"UNKNOWN","sponsor":"Markus Zeitlinger","startDate":"2018-10-01","conditions":"Peritonitis, Pneumonia","enrollment":20},{"nctId":"NCT04167228","phase":"","title":"Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2019-10-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":348},{"nctId":"NCT04358991","phase":"","title":"Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2017-01-01","conditions":"Bacterial Infections","enrollment":20},{"nctId":"NCT04402359","phase":"","title":"Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2018-07-05","conditions":"Ventilator Associated Pneumonia","enrollment":200},{"nctId":"NCT03941951","phase":"NA","title":"Study to Optimize the Use of New Antibiotics","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-07-09","conditions":"Bacterial Infections, Fungal Infection","enrollment":900},{"nctId":"NCT03243864","phase":"","title":"Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis","status":"UNKNOWN","sponsor":"Temple University","startDate":"2017-03-13","conditions":"Renal Failure, Bacterial Infections, Critical Illness","enrollment":10},{"nctId":"NCT02822950","phase":"PHASE1","title":"A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2017-01","conditions":"Pharmacokinetics of Avycaz in ICU Patients","enrollment":10},{"nctId":"NCT02504827","phase":"PHASE4","title":"Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2015-09","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT02475733","phase":"PHASE2","title":"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-01","conditions":"Complicated Intra-abdominal Infections","enrollment":83},{"nctId":"NCT02497781","phase":"PHASE2","title":"Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-24","conditions":"Complicated Urinary Tract Infections","enrollment":97},{"nctId":"NCT00752219","phase":"PHASE2","title":"Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03-31","conditions":"Complicated Intra-abdominal Infections","enrollment":204},{"nctId":"NCT00690378","phase":"PHASE2","title":"Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Complicated Urinary Tract Infection","enrollment":137},{"nctId":"NCT01644643","phase":"PHASE3","title":"Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-01","conditions":"Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection","enrollment":345},{"nctId":"NCT01599806","phase":"PHASE3","title":"Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","enrollment":641},{"nctId":"NCT01726023","phase":"PHASE3","title":"Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-01","conditions":"Complicated Intra-abdominal Infection","enrollment":486},{"nctId":"NCT01499290","phase":"PHASE3","title":"Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Complicated Intra-Abdominal Infection","enrollment":493},{"nctId":"NCT01808092","phase":"PHASE3","title":"A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)","enrollment":969},{"nctId":"NCT01595438","phase":"PHASE3","title":"Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","enrollment":598},{"nctId":"NCT01893346","phase":"PHASE1","title":"Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Systemic Infections","enrollment":35},{"nctId":"NCT01920399","phase":"PHASE1","title":"A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT01789528","phase":"PHASE1","title":"A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-08","conditions":"Pharmacokinetics, Open Label, CAZ-AVI","enrollment":48},{"nctId":"NCT01534247","phase":"PHASE1","title":"A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT01291602","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Healthy Male and Female Japanese Volunteers","enrollment":15},{"nctId":"NCT01430910","phase":"PHASE1","title":"A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":"Healthy","enrollment":43},{"nctId":"NCT01395420","phase":"PHASE1","title":"Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-08","conditions":"Healthy","enrollment":45},{"nctId":"NCT01290900","phase":"PHASE1","title":"A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Healthy Male Volunteers","enrollment":54},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2}],"_emaApprovals":[],"_faersSignals":[{"count":99,"reaction":"DEATH"},{"count":58,"reaction":"OFF LABEL USE"},{"count":42,"reaction":"DRUG INEFFECTIVE"},{"count":41,"reaction":"PATHOGEN RESISTANCE"},{"count":19,"reaction":"TREATMENT FAILURE"},{"count":16,"reaction":"ACUTE KIDNEY INJURY"},{"count":16,"reaction":"PRODUCT USE ISSUE"},{"count":16,"reaction":"SEPTIC SHOCK"},{"count":15,"reaction":"DRUG RESISTANCE"},{"count":15,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":2439,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avycaz"],"phase":"marketed","status":"active","brandName":"Ceftazidime-avibactam","genericName":"Ceftazidime-avibactam","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftazidime-avibactam is a combination antibiotic used to treat severe Gram-negative bacterial infections. It works by inhibiting bacterial penicillin-binding proteins, a mechanism that is targeted by the small molecule ceftazidime, which is combined with avibactam to enhance its effectiveness.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}